Abstract
Cancer testing is one of the most important growth opportunities for the next
three to five years in the diagnostics segment. The National Cancer Institute
estimates that about ten million Americans have or have had some form of
cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical
companies are developing more than 300 new medicines for cancer, some of which
are in development for more than one type of the disease, for a total of more
than 500 ongoing R&D projects. The goal of this TriMark Publications report is
to review the market for tumor marker testing equipment and supplies using
screening reagents and instruments for analysis of individual components in
blood, serum or plasma. It defines the dollar volume of sales, both worldwide
and in the U.S., and analyzes the factors that influence the size and the
growth of the market segments. Also examined are the subsections of each
market segment, including: the physician office labs, hospital labs and
commercial laboratories. Additionally, the numbers of institutions using this
type of testing and the factors that influence purchases are discussed. The
report surveys almost all of the companies known to be marketing,
manufacturing or developing instruments and reagents for the clinical
point-of-care market in the U.S. Each company is discussed in depth with a
section on its history, product line, business and marketing analysis, and a
subjective commentary of the company' s market position.
By Purchasing This Report You Will Have:
- An improved understanding of the current state and future of the cancer
diagnostic testing market.
- The latest information on the leading companies engaged in research and
development and products in the pipeline.
- The leading perspective of recent cancer diagnostic developments and
revelations.
- Knowledge of the cancer diagnostics market as an area of growth, research
and investment.
Analysis includes the use of charts and graphs measuring product growth and
trends within the marketplace. In addition, a discussion of research into the
cancer diagnostics arena provides the reader with a deeper understanding of
the possibilities for future treatment and avenues for possible research and
development budgets. Company-specific information, including sales figures,
product pipeline status and research and development trends is provided
throughout the report. The report will:
- Identify viable technology drivers through a comprehensive look at
platform technologies for cancer diagnostics, including, probe-based nucleic
acid assays, microarrays and sequencing.
- Obtain a complete understanding of the chief cancer diagnostics
tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and
theranostic-from their basic principles to their applications.
- Discover feasible market opportunities by identifying high-growth
applications in different clinical diagnostic areas, focusing on the biggest
and expanding markets in oncology.
- Focus on global industry development through an in-depth analysis of the
major world markets for cancer diagnostics, including growth forecasts.
This report answers the following questions in this report:
- What are the near-term business opportunities in the cancer diagnostics
market?
- What are the current and forecasted sizes of the cancer diagnostics market?
- What are the business models currently used by companies in cancer
diagnostics?
- How will manufacturers, researchers, physicians, patients and payers
influence the cancer diagnostics market?
- What are the drivers and bottlenecks influencing the cancer diagnostics
market?
- What are the technologies used in the cancer diagnostics sector?
- Who holds the proprietary rights to cancer diagnostics market technology?
- What are current applications of this technology?
- What regulatory processes must cancer diagnostics undergo in the United
States, Japan and Europe?
- How will new cancer diagnostics change treatment and payment paradigms?
- How will cancer diagnostic testing reduce healthcare expenditures?
| 
View Cart
